In addition, intranasal delivery of CCL2 increases CD4+ T cell recruitment to the premetastatic niche of the lung, and this correlates with enhanced seeding and growth of tumor cells [183], while CCL2 shows a potential antitumor activity in tumor-entrained neutrophil-mediated tumor killing in vitro. The gene discussed is CCL2; the disease is neoplasm.